ProQR Therapeutics/$PRQR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ProQR Therapeutics
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Ticker
$PRQR
Sector
Primary listing
Employees
166
Headquarters
Website
PRQR Metrics
BasicAdvanced
$233M
-
-$0.47
0.43
-
Price and volume
Market cap
$233M
Beta
0.43
52-week high
$4.04
52-week low
$1.07
Average daily volume
258K
Financial strength
Current ratio
3.756
Quick ratio
3.693
Long term debt to equity
15.647
Total debt to equity
25.174
Interest coverage (TTM)
-38.87%
Profitability
EBITDA (TTM)
-47.513
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-231.45%
Operating margin (TTM)
-244.24%
Effective tax rate (TTM)
-0.05%
Revenue per employee (TTM)
$115,830
Management effectiveness
Return on assets (TTM)
-20.47%
Return on equity (TTM)
-79.47%
Valuation
Price to revenue (TTM)
10.901
Price to book
3.48
Price to tangible book (TTM)
3.48
Price to free cash flow (TTM)
-4.351
Free cash flow yield (TTM)
-22.99%
Free cash flow per share (TTM)
-0.508
Growth
Revenue change (TTM)
8.65%
Earnings per share change (TTM)
51.62%
3-year revenue growth (CAGR)
64.34%
10-year revenue growth (CAGR)
28.51%
3-year earnings per share growth (CAGR)
-22.47%
10-year earnings per share growth (CAGR)
-5.42%
What the Analysts think about PRQR
Analyst ratings (Buy, Hold, Sell) for ProQR Therapeutics stock.
PRQR Financial Performance
Revenues and expenses
PRQR Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ProQR Therapeutics stock?
ProQR Therapeutics (PRQR) has a market cap of $233M as of August 22, 2025.
What is the P/E ratio for ProQR Therapeutics stock?
The price to earnings (P/E) ratio for ProQR Therapeutics (PRQR) stock is 0 as of August 22, 2025.
Does ProQR Therapeutics stock pay dividends?
No, ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders as of August 22, 2025.
When is the next ProQR Therapeutics dividend payment date?
ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders.
What is the beta indicator for ProQR Therapeutics?
ProQR Therapeutics (PRQR) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.